{"id":"NCT05420961","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)","officialTitle":"A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-07-12","primaryCompletion":"2023-05-16","completion":"2023-05-16","firstPosted":"2022-06-16","resultsPosted":"2024-05-01","lastUpdate":"2024-10-26"},"enrollment":717,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumonia, Pneumococcal"],"interventions":[{"type":"BIOLOGICAL","name":"V116","otherNames":["Pneumococcal 21-valent Conjugate Vaccine"]},{"type":"BIOLOGICAL","name":"PCV15","otherNames":["VAXNEUVANCE™"]},{"type":"BIOLOGICAL","name":"PPSV23","otherNames":["PNEUMOVAX™23"]}],"arms":[{"label":"Cohort 1: V116","type":"EXPERIMENTAL"},{"label":"Cohort 1: PCV15","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 2: V116","type":"EXPERIMENTAL"},{"label":"Cohort 2: PPSV23","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 3: V116","type":"EXPERIMENTAL"}],"summary":"This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.","primaryOutcome":{"measure":"Percentage of Participants With Solicited Injection-site Adverse Events (AEs)","timeFrame":"Up to 5 days post-vaccination","effectByArm":[{"arm":"Cohort 1: V116","deltaMin":7.4,"sd":null},{"arm":"Cohort 1: PCV15","deltaMin":7.7,"sd":null},{"arm":"Cohort 2: V116","deltaMin":7.5,"sd":null},{"arm":"Cohort 2: PPSV23","deltaMin":9.4,"sd":null},{"arm":"Cohort 3: V116","deltaMin":7.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":51,"countries":["United States","Canada","France","Israel","Italy","Japan","South Korea","Spain","Taiwan"]},"refs":{"pmids":["39082735"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26093&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":230},"commonTop":["Injection site pain","Fatigue","Headache","Injection site swelling","Injection site erythema"]}}